Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice

Dual Inhibition of the Endothelin and Angiotensin Receptor Ameliorates Renal and Inner Ear Pathologies in Alport Mice

Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis

Differentiating Primary and Secondary FSGS Using Non-Invasive Urine Biomarkers

Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the Parasol Initiative

The Dual Endothelin A and Angiotensin II Type 1 Receptor Antagonist Sparsentan (FILSPARI®) Exhibits a Safe Nonclinical Male Fertility Toxicity Profile

Efficacy and Safety of Immunosuppressive Therapy in Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis

Mechanism of Protective Actions of Sparsentan in the Kidney: Lessons From Studies in Models of Chronic Kidney Disease

Sparsentan. Dual Angiotensin II AT1 Receptor Blocker and Endothelin ETA Receptor Antagonist, Treatment of Focal Segmental Glomerulosclerosis, Treatment of IgA Nephropathy

Dual Inhibition of Renin-Angiotensin-Aldosterone System and Endothelin-1 in Treatment of Chronic Kidney Disease

Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis

Sparsentan: The First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile